Daryl Thompson, founder of GRDG Sciences LLC (“GRDG”) in Winter
Haven, Florida, has spent a career working just out of the
spotlight and inventing biological and medical technologies that,
when fully deployed, could better the lives of people around the
world.
But all that may change as GRDG, a scientific
research partner of Impact BioMedical, Inc., a wholly owned
subsidiary of DSS, Inc. (NYSE American: DSS), announced
today that it will be the subject of a documentary film
highlighting the passion, the search, and the cutting-edge
discoveries that push the company — and its founder —
behind a single-minded goal: creating a healthier world quickly and
naturally.
“We are thrilled to take the audience behind the scenes and
around the world to discover solutions to problems that have
plagued humanity for thousands of years,” said Thompson. “From the
Florida Everglades to the rainforests of South America to the
jungles of Africa and beyond, we’re going to show everyone what we
do and how we do it.”
The documentary project comes on the heels of GRDG’s completion
of Sombrero, a five-year multi-pronged project that yielded
multiple patents and potentially billions of dollars in licensing
opportunities. But it also paved the way for something deeper.
“Sombrero allowed us to make discoveries, for sure, but it also
allowed us to create a template for problem solving that I think
can be duplicated around the world,” said Thompson. “That is part
of what the film is about, the blueprint to forming several
quick-thinking, fast-acting groups around the world that can
identify potential problems and create solutions outside the
traditional channels that aren’t able to move as fast.”
For GRDG, that team included a Washington insider, an investor,
and a lab.
A Real-Life Mr. PhelpsFor Dr. Roscoe Moore,
retired United States Assistant Surgeon General and former Epidemic
Intelligence Services Officer at the U.S. Centers for Disease
Control, meeting Thompson and understanding his approach led to a
creative partnership.
“Daryl came to me about six years ago, and we met a couple
times, and lo and beyond, I became an advisor,” said Dr. Moore. “I
don’t endorse any specific product — I never have; but I just
look at the science and the science says that what he’s doing
works.”
Moore, who is now GRDG’s Chief Scientific Advisor, said that
Thompson’s model of getting things done is something that is vital
in this day and age.
“The NIH model is great for research, but it takes a long time
to get anything done,” he said. “Big government operations are not
meant to be stealth. We needed someone to get things done in a way
that cuts through the red tape without cutting corners. In that
regard, Daryl’s efforts have been stellar.”
For Thompson, Moore is more than just an advisor.
“Roscoe is our Mr. Phelps,” said Thompson, referring to the
director of the Impossible Mission Force. “He would tell us about
several different directions and problems that needed solving and
then gave us the freedom to choose which one to solve.”
That partnership led GRDG to discover several breakthrough
technologies that could tackle unmet global problems,
including:
- Linebacker: Multi-faceted therapeutic platform
for metabolic, neurologic, cancer, and infectious diseases created
to mirror the Panacea Project, a U.S. Defense Advanced Research
Projects Agency (DARPA) program to provide novel, multi-target
therapeutics for unmet physiological needs.
- 3F Biofragrance: For mosquito avoidance and
antimicrobial protection with confirmed in vitro effectiveness
against MRSA, E. coli, Tuberculosis and SARS-CoV-2 (COVID-19). This
technology is a surface disinfectant and is also designed to be
incorporated into the Open Air Defense Initiative for protection
against outbreaks by protecting key points where the potential
spread of pathogens occur.
- Equivir: A patented Over the Counter (OTC)
medication successfully tested in vitro against Rhinovirus,
Influenza, Cholera, SARS-CoV-2 (COVID-19) and in a Biosafety Level
4 facility, Ebola. Equivir/Nemovir is both a treatment and a
prophylactic for COVID-19 and is moving to human clinical
trials.
- Quantum: The solution to the Patent Cliff
accomplished by creating a new class of medicinal chemistry that
uses advanced methods to increase effectiveness and persistence of
natural compounds and existing drugs. The safety attributes of the
original molecules are maintained. Typically, drug discovery
processes modify functional groups.
- Bioplastics: Antimicrobial plastics for
consumer products that control the spread of active pathogens such
as SARS-CoV-2, Influenza, E. coli, Staph, and Rhinovirus, by
exploiting key strategies found in the biological realm. These new
plastics are specifically focused on solutions for common products
such as cups, plates, utensils, plastic bags, and countertops. The
first prototypes have completed antimicrobial resistance
testing.
Having an ImpactEarly in the development
process, GRDG began a working relationship with Impact Biomedical,
who partnered with GRDG and provided investment capital to support
its research.
“We saw an excellent opportunity to partner with Daryl and his
team to accomplish something that has the potential to have a
direct impact on the lives of millions of people around the world,”
said Frank. D. Heuszel, President and Director of Impact
BioMedical, Inc. “The ability to analyze the problem and creatively
see a solution that can be disseminated quickly and without a
relatively long lead team is special.”
Going ProThe next key partner in GRDG’s pursuit
of innovation came in a partnership with ProPhase Labs, which
proposes to turn Thompson’s research into real-life products.
“For us, the science has to make sense,” said ProPhase Executive
Vice President and COO Alice Lioi. “Daryl has formulated products
that performed well in pre-clinical trials and the fact that they
are based on natural substances is a different approach that we
believe can strengthen products in the human world.”
While Moore, Impact, and ProPhase have all played key roles in
GRDG’s research and development, it has been Thompson who may be
the revelation of the documentary.
“I have always enjoyed working behind the scenes, working
alongside government entities, but outside the trappings of
bureaucracy — that’s where the real innovation takes place,” said
Thompson. “But the work we have done for the past five years could
have such an impact on the world, we just had to tell this story.
So that’s what we’re doing. Parts of this story may sound
impossible — trust me, I sometimes shake my head at the things
we’ve been able to create — but at the end of the day, it still
rings true.”
Diamond Studios, an Emmy Award-winning production company from
Tampa, Fla., will produce the documentary, which will begin filming
in December 2022.
About Impact BioMedical, Inc.Impact BioMedical,
Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS.
Impact BioMedical strives to leverage its scientific know-how and
intellectual property rights to provide solutions that have been
plaguing the biomedical field for decades. By tapping into the
scientific expertise of GRDG Sciences, LLC, Impact BioMedical
pledges to undertake a concerted effort in the R&D, drug
discovery and development for the prevention, inhibition, and
treatment of neurological, oncological and immuno -related
diseases. For more information on Impact BioMedical
visit http://impbio.com/.
About DSS, Inc.DSS is a multinational company
operating businesses within nine divisions: Product Packaging,
Biotechnology, Direct Marketing, Commercial Lending, Securities and
Investment Management, Alternative Trading, Digital Transformation,
Secure Living, and Alternative Energy. DSS strategically acquires
and develops assets to enrich the value of its shareholders through
calculated IPO spinoffs and a parametric share distribution
strategy. Since 2019, under the guidance of new leadership, DSS has
built the necessary foundation for achievable growth through the
formation of a diversified portfolio of companies positioned to
drive profitability in multiple high growth sectors. These
companies offer innovative, flexible, and real-world solutions that
not only provide mutual benefits for businesses and their
customers, but also create sustainable value and opportunity for
transformation.
For more information on DSS
visit http://www.dssworld.com.
Investor Contact:Dave Gentry, CEORedChip Companies
Inc.407-491-4498DSS@redchip.com
Safe Harbor DisclosureThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking
statements include, but are not limited to, statements related to
the Company's intended use of proceeds and other statements that
are not historical facts. Forward-looking statements are based on
management's current expectations and are subject to risks and
uncertainties that may cause actual results or events to differ
materially from those projected. These risks and uncertainties,
many of which are beyond our control, include: risks relating to
our growth strategy; our ability to obtain, perform under and
maintain financing and strategic agreements and relationships;
risks relating to the results of development activities; our
ability to attract, integrate and retain key personnel; our need
for substantial additional funds; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings, including, without limitation, our reports on Forms 8-K,
10-K and 10-Q, all of which can be obtained on the SEC website at
www.sec.gov. Readers are cautioned not to place undue reliance on
the forward-looking statements, which speak only as of the date on
which they are made and reflect management's current estimates,
projections, expectations, and beliefs. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions, or circumstances on which any such statement is based,
except as required by law.
DSS (AMEX:DSS)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
DSS (AMEX:DSS)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024